EMA approves of Pfizer biosimilar trastuzumab, Trazimera®

Jul 31, 2018

Pfizer announces EMA approval of biosimilar trastuzumab, Trazimera® for the treatment of human epidermal growth factor (HER2+) breast cancer and HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma.  This is Pfizer’s 4th biosimilar to receive EU approval.

Print Page Mail Article